GlassScriptPhysician profile
Pragati Shukla
NPI 1891722195
$3,786.32
in general payments reported to CMS, 2019-2025
39 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $263 · 2021: $58.92 · 2022: $400 · 2023: $684 · 2024: $789 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $791.73 | 2019-2025 | |
| Abbvie INC. | $435.15 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $314.47 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $271.37 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $260.20 | 2019-2024 | Ultomiris |
| Lundbeck LLC | $189.33 | 2023-2024 | Vyepti |
| Biogen, INC. | $183.24 | 2019-2023 | Vumerity |
| Ge Healthcare | $134.89 | 2019-2024 | |
| Genentech USA, INC. | $120.80 | 2019-2025 | Enspryng, Ocrevus |
| Emd Serono, INC. | $98.19 | 2019 | |
| Amgen INC. | $96.87 | 2019-2024 | Uplizna |
| Pfizer INC. | $89.09 | 2023-2025 | |
| Axsome Therapeutics, INC. | $75.53 | 2025 | Symbravo |
| Allergan, INC. | $54.15 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $45.34 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.88 | 2025 | Wainua |
| Grifols USA, LLC | $41.52 | 2024-2025 | Gamunex-C |
| Teva Pharmaceuticals USA, INC. | $39.23 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $37.15 | 2022-2023 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $37.10 | 2024 | Acthar |
| Csl Behring | $36.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.06 | 2024 | Hyqvia |
| Ucb, INC. | $28.02 | 2022 | |
| Acorda Therapeutics, INC | $27.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.64 | 2022 | |
| Eisai INC. | $24.52 | 2023 | |
| Lilly USA, LLC | $23.87 | 2019 | |
| Celgene Corporation | $22.90 | 2025 | Zeposia |
| Scilex Pharmaceuticals INC. | $22.83 | 2024 | |
| Bausch Health US, LLC | $22.59 | 2019 | |
| Avion Pharmaceuticals | $22.38 | 2023 | Dhivy |
| Portola Pharmaceuticals, LLC | $21.30 | 2019 | |
| Neurelis, INC. | $21.15 | 2023 | Valtoco |
| Argenx US, INC. | $20.62 | 2024 | Vyvgart |
| Avanir Pharmaceuticals, INC. | $18.34 | 2019 | |
| Tg Therapeutics, INC. | $18.02 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.57 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.06 | 2023 | Rytary |
| Akcea Therapeutics, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pragati Shukla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.